• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

GILTERITINIB Drug Record

  • Summary
  • Interactions
  • Claims
  • GILTERITINIB chembl:CHEMBL3301622 ApprovedAntineoplastic

    Alternate Names:

    GILTERITINIB
    ASP-2215
    ASP2215
    chemidplus:1254053-43-4
    pubchem.compound:49803313
    drugbank:12141
    chembl:CHEMBL3301622

    Drug Info:

    (4 More Sources)

    Publications:

    Antar A et al., 2017, Inhibition of FLT3 in AML: a focus on sorafenib., Bone Marrow Transplant
    Thom C, 2015, Preliminary data on ASP2215: tolerability and efficacy in acute myeloid leukemia patients., Future Oncol
    Mori M et al., 2017, Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia., Invest New Drugs
    Perl AE et al., 2019, Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AML., N Engl J Med
    Perl et al., 2017, Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study., Lancet Oncol.
    Tarver TC et al., 2020, Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations., Blood Adv
  • GILTERITINIB   AXL

    Interaction Score: 6.18

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Tyrosine-protein kinase receptor UFO inhibitor
    Direct Interaction yes

    PMIDs:
    27775694 26279055 28516360


    Sources:
    ChemblInteractions TTD

  • GILTERITINIB   FLT3

    Interaction Score: 4.73

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type acute myeloid leukemia
    Response Type predicted – sensitive
    Approval Status Phase Ib/II

    PMIDs:
    28516360 31665578 28645776 32040554 27775694 26279055


    Sources:
    JAX-CKB ChemblInteractions CIViC PharmGKB TTD FDA OncoKB

  • JAX-CKB: Gilteritinib

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Perl et al., 2017, Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study., Lancet Oncol.

  • CIViC: GILTERITINIB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Perl et al., 2017, Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study., Lancet Oncol.
    Mori M et al., 2017, Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia., Invest New Drugs
    Perl AE et al., 2019, Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i>-Mutated AML., N Engl J Med

  • TTD: Gilteritinib

    • Version: 2020.06.01

    Alternate Names:
    D04KZY TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL3301622

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • OncoKB: Gilteritinib

    • Version: 23-July-2020

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL3301622

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • PharmGKB: gilteritinib

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Gilteritinib

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21